Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

[1]  W. Zong,et al.  DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer , 2021, Communications Biology.

[2]  B. Győrffy,et al.  Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer , 2021, Computational and structural biotechnology journal.

[3]  T. Ger,et al.  GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy , 2021, Journal of personalized medicine.

[4]  F. Marcucci,et al.  Glycolysis-induced drug resistance in tumors—A response to danger signals? , 2021, Neoplasia.

[5]  H. Haro,et al.  Gemcitabine and Rapamycin Exhibit Additive Effect against Osteosarcoma by Targeting Autophagy and Apoptosis , 2020, Cancers.

[6]  Yingying Xu,et al.  Metabolic Reprogramming in Triple-Negative Breast Cancer , 2020, Frontiers in Oncology.

[7]  Mo-Fang Liu,et al.  hENT1 Reverses Chemoresistance by Regulating Glycolysis in Pancreatic Cancer. , 2020, Cancer letters.

[8]  Chenfang Dong,et al.  Metabolic reprogramming in triple-negative breast cancer , 2020, Cancer biology & medicine.

[9]  M. Zheng,et al.  Discovery of novel glyceraldehyde-3-phosphate dehydrogenase inhibitor via docking-based virtual screening. , 2020, Bioorganic chemistry.

[10]  L. Ding,et al.  MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer , 2019, Cells.

[11]  S. Moriya,et al.  Involvement of Dual Strands of miR-143 (miR-143-5p and miR-143-3p) and Their Target Oncogenes in the Molecular Pathogenesis of Lung Adenocarcinoma , 2019, International journal of molecular sciences.

[12]  A. Damjanović,et al.  Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge , 2019, Cells.

[13]  Juan Li,et al.  Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer , 2019, Molecular Cancer.

[14]  J. Steinbach,et al.  Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide , 2019, International journal of molecular sciences.

[15]  K. Polyak,et al.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. , 2019, Cancer discovery.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  J. W. Allwood,et al.  Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1) , 2018, Diabetes, obesity & metabolism.

[18]  A. Schneeweiss,et al.  nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Johan Hartman,et al.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.

[20]  J. Steyaert,et al.  How the Warburg effect supports aggressiveness and drug resistance of cancer cells? , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  F. Rumjanek,et al.  Metabolic Reprogramming During Multidrug Resistance in Leukemias , 2018, Front. Oncol..

[22]  N. Davidson,et al.  Practical Approach to Triple-Negative Breast Cancer. , 2017, Journal of oncology practice.

[23]  Bernhard Kuster,et al.  Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis. , 2017, Cancer research.

[24]  K. Jensen,et al.  Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance , 2017, Clinical Cancer Research.

[25]  I. Coe,et al.  Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1) , 2016, Nucleosides, nucleotides & nucleic acids.

[26]  S. McCall,et al.  TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. , 2016, Carcinogenesis.

[27]  Min Zhang,et al.  18F-FDG PET/CT for Monitoring the Response of Breast Cancer to miR-143-Based Therapeutics by Targeting Tumor Glycolysis , 2016, Molecular therapy. Nucleic acids.

[28]  Longyang Jiang,et al.  miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. , 2016, Gynecologic oncology.

[29]  J. Roa,et al.  Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy‐naïve pT2 gallbladder adenocarcinoma patients , 2016, Histopathology.

[30]  E. Giovannetti,et al.  Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective , 2016, Cancer Chemotherapy and Pharmacology.

[31]  G. Stassi,et al.  Epithelial–mesenchymal transition: a new target in anticancer drug discovery , 2016, Nature Reviews Drug Discovery.

[32]  M. Boroujerdi,et al.  Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  T. Boonmars,et al.  Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. , 2015, International journal of oncology.

[34]  J. Ragaz,et al.  Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[35]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[36]  Gisele Monteiro,et al.  Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. , 2014, European journal of pharmacology.

[37]  A. Maitra,et al.  An Essential Mesenchymal Function for miR-143/145 in Intestinal Epithelial Regeneration , 2014, Cell.

[38]  Carol E. Cass,et al.  Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity , 2013, Clinical Cancer Research.

[39]  J. Ai,et al.  miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. , 2013, Cancer letters.

[40]  P. Nelson,et al.  Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance , 2012, Clinical Cancer Research.

[41]  H. Ji,et al.  MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene* , 2012, The Journal of Biological Chemistry.

[42]  Yong Li,et al.  A novel miR‐155/miR‐143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells , 2012, The EMBO journal.

[43]  A. Dueñas-González,et al.  DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells , 2012, PloS one.

[44]  Ahmedin Jemal,et al.  Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[45]  J. Hicks,et al.  Insight into the heterogeneity of breast cancer through next-generation sequencing. , 2011, The Journal of clinical investigation.

[46]  Ellen Warner,et al.  Clinical practice. Breast-cancer screening. , 2011, The New England journal of medicine.

[47]  S. Verma,et al.  Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. , 2011, Current oncology.

[48]  B. Albensi,et al.  Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic‐ischemic conditions , 2011, Journal of neurochemistry.

[49]  Joydeep Mukherjee,et al.  Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme , 2011, The Journal of experimental medicine.

[50]  E. Rooij,et al.  The Art of MicroRNA Research , 2011 .

[51]  Carol Cass,et al.  Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer , 2010, Journal of cellular physiology.

[52]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[53]  Saroj P. Mathupala,et al.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. , 2009, Seminars in cancer biology.

[54]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[55]  A. Tsodikov,et al.  The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004 , 2008, Cancer.

[56]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[57]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  D. M. Parkin,et al.  Use of Statistics to Assess the Global Burden of Breast Cancer , 2006, The breast journal.

[59]  J. Mackey,et al.  cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. , 2005, Lung cancer.

[60]  A. Nakao,et al.  Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[61]  L. Brinton,et al.  Global trends in breast cancer incidence and mortality 1973-1997. , 2005, International journal of epidemiology.

[62]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[63]  V. Heinemann.  Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer , 2003, Oncology.

[64]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[65]  P. Boffetta,et al.  Cancer in developing countries , 1994, CA: a cancer journal for clinicians.

[66]  C. Cass,et al.  A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin). , 1992, Cancer research.

[67]  C. Wolf,et al.  Molecular mechanisms of drug resistance. , 1990, The Biochemical journal.

[68]  C. Cass,et al.  Absence of binding sites for the transport inhibitor nitrobenzylthioinosine on nucleoside transport-deficient mouse lymphoma cells. , 1981, Biochimica et biophysica acta.

[69]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[70]  Y. Miao,et al.  Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[71]  Hongming Song,et al.  miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. , 2017, American journal of translational research.

[72]  John R. Mackey,et al.  Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. , 2014, Journal of the National Cancer Institute.

[73]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[74]  Dolors Colomer,et al.  Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. , 2006, Haematologica.

[75]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[76]  J. Mackey,et al.  Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[78]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[79]  J. Mackey,et al.  Nucleoside transport and its significance for anticancer drug resistance. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.